NFE2L1 activator-1
Based on 1 Customer Validation
NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.93%
- CAS. Nr.: 3070514-51-8
- Formel: C26H31NO7S
- Molecular Weight:501.59
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biologische Aktivität
NFE2L1 activator-1 potently activates NFE2L1-mediated transcription in HEK293 cells, with an EC50 of 2.4 μM[1].
NFE2L1 activator-1 (3 μM; 24 h) protects neuroblastoma SH-SY5Y cells against ferroptosis induced by erastin, RSL3 and FAC[1].
Treatment of SH-SY5Y neuroblastoma cells with NFE2L1 activator-1 (3 μM; 16 h) for 16 h upregulates the transcription of target genes of NFE2L1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 cells expressing HA-tagged NFE2L1
-
Concentration:3 μM
-
Incubation Time:16 h
-
Result:Stabilized the glycosylated (G) and deglycosylated full-length (FL) forms of both NFE2L1-HA and HA-NFE2L1.
Detected the proteolytically cleaved, transcriptionally active form (P) of NFE2L1-HA.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:3 μM
-
Incubation Time:16 h
-
Result:Increased transcription levels of NFE2L1 target gene GPX4.
Increased transcription levels of NFE2L1 target gene PSMB7.
Increased transcription levels of NFE2L1 target gene PSMC4.
Chemical Information
-
CAS. Nr. 3070514-51-8
-
Appearance Solid
-
Molecular Weight 501.59
-
Formel C26H31NO7S
-
Color Light yellow to yellow
-
SMILES
COC1=C(OC)C=CC(/C=C2CC(NS(=O)(CC)=O)C/C(C\2=O)=C\C3=CC=C(OC)C(OC)=C3)=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (199.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (9.97 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9937 mL | 9.9683 mL | 19.9366 mL | 49.8415 mL |
| 5 mM | 0.3987 mL | 1.9937 mL | 3.9873 mL | 9.9683 mL | |
| 10 mM | 0.1994 mL | 0.9968 mL | 1.9937 mL | 4.9842 mL | |
| 15 mM | 0.1329 mL | 0.6646 mL | 1.3291 mL | 3.3228 mL | |
| 20 mM | 0.0997 mL | 0.4984 mL | 0.9968 mL | 2.4921 mL | |
| 25 mM | 0.0797 mL | 0.3987 mL | 0.7975 mL | 1.9937 mL | |
| 30 mM | 0.0665 mL | 0.3323 mL | 0.6646 mL | 1.6614 mL | |
| 40 mM | 0.0498 mL | 0.2492 mL | 0.4984 mL | 1.2460 mL | |
| 50 mM | 0.0399 mL | 0.1994 mL | 0.3987 mL | 0.9968 mL | |
| 60 mM | 0.0332 mL | 0.1661 mL | 0.3323 mL | 0.8307 mL | |
| 80 mM | 0.0249 mL | 0.1246 mL | 0.2492 mL | 0.6230 mL | |
| 100 mM | 0.0199 mL | 0.0997 mL | 0.1994 mL | 0.4984 mL |
NFE2L1 activator-1 Related Classifications
HY-178997 Related Classifications
Powered by Bioz